Frankfurt - Delayed Quote EUR

Novo Nordisk A/S (NOVA.F)

77.00

-0.20

(-0.26%)

At close: January 22 at 9:52:28 PM GMT+1

Novo Nordisk (NVO) Stock Dips While Market Gains: Key Facts

In the latest trading session, Novo Nordisk (NVO) closed at $80.57, marking a -0.57% move from the previous day.

Zacks 6 hours ago

NVO
GLP-1 Drugs Cut Risk of Alzheimer's, NVO & LLY Shares Rise

Shares of Novo Nordisk and Eli Lilly gain following study results that show GLP-1 drugs cut the risk of heart and kidney diseases as well certain brain ailments.

Zacks 15 hours ago

NVO

LLY
This Biotech Stock Soared 116% in 2024, but Is It a Buy in 2025?

One of the hottest growth areas in the healthcare landscape these days is the obesity drug market because of a class of drugs that's proven to be both efficacious and safe in clinical studies and in the real world. You might be familiar with the top sellers, such as Eli Lilly's Zepbound or Novo Nordisk's Wegovy -- they've made headlines as demand for them soared. The obesity drug market may reach beyond $100 billion by 2030, according to Morgan Stanley Research.

Motley Fool 20 hours ago

VKTX

NVO

LLY
Novo Nordisk's GLP-1 Drugs: Health Breakthroughs, Big Buybacks, and Medicare's Price-Cut Threat

From Alzheimer's prevention to weight-loss dominance, Novo bets on innovation and share repurchases amid Medicare pressure.

GuruFocus.com yesterday

NVO

LLY
Novo, Lilly Weight-Loss Drugs Reduce Risk of Alzheimer’s, Study Shows. What It Means for the Stocks.

Weight-loss and diabetes drugs reduced the risk of developing Alzheimer’s, an independent study published Monday showed. The big pharma companies Novo Nordisk and Eli Lilly look to be the main benefactors of GLP-1 medications turning into a “catch-all pill,” mitigating a raft of health conditions beyond obesity and diabetes amid increased competition in the weight-loss space. Researchers have now mapped the effectiveness and risks of GLP-1 agonists in the largest study to date of their health impact beyond diabetes and weight-loss.

Barrons.com yesterday

LLY

NVO
Company News for Jan 21, 2025

Companies In The Article Are: INTC, NVO, VST, JBHT

Zacks yesterday

INTC

NVO

JBHT
Will Medicare End Ozempic Maker Novo Nordisk's Obesity Drug Boom?

Few drugs have generated as much excitement as Novo Nordisk's (NYSE: NVO) Ozempic and Wegovy. In June 2021, Novo Nordisk won FDA approval for Ozempic's sibling, Wegovy, both of which share the same active ingredient (semaglutide), as a treatment for chronic weight management. The two drugs are Novo Nordisk's top growth drivers, and together comprise over 60% of its total revenue.

Motley Fool yesterday

NVO
The race for the next Ozempic is on

Two recent disappointing clinical trials of highly-anticipated weight-loss drugs have made it clear that it is too early to crown any winners in the race for the next generation of anti-obesity treatments.

Quartz yesterday

NVO

LLY

VKTX
LVMH Surges Past Novo Nordisk as Arnault's Wealth Skyrockets--Is Luxury Back on Track?

LVMH Reclaims Europe's Top Spot as Arnault Adds $15 Billion--What Investors Need to Know Now.

GuruFocus.com 2 days ago

MC.PA

NVO
NVO Stock Down as Medicare Selects Semaglutide Drugs for Price Cuts

Novo Nordisk stock falls as Medicare selects its marketed semaglutide medicines catering to T2D and obesity for price negotiations in 2025.

Zacks 2 days ago

NVO

LLY
Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 20 January 2025 – On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. Under the programm

GlobeNewswire 2 days ago

NONOF

NVO
Company News for Jan 20, 2025

Companies In The Article Are: INTC, NVO, VST, JBHT

Zacks 2 days ago

INTC

NVO

JBHT
LVMH dethrones Novo Nordisk as Europe’s most valuable company as Bernard Arnault adds $12 billion to net worth in 2025

Novo Nordisk has faced a massive selloff in recent months amid disappointing drug trials and U.S. pressure to cut its prices.

Fortune 2 days ago

NVO
Trending tickers: Trump Media, Intel, Alibaba, Novo Nordisk and Entain

The latest investor updates on stocks that are trending on Monday.

Yahoo Finance UK 2 days ago

TCEHY

TCTZF

LVMHF
Novo Nordisk’s high-dose Wegovy increases weight loss and remains safe

The therapy was reported to be well-tolerated, with a good safety profile.

Clinical Trials Arena 2 days ago

NVO
Jim Cramer’s Comments on Novo Nordisk A/S (NVO) Surrounded Its Weight Loss Drugs Being Picked For Medicare Price Negotiations

We recently compiled a list of the Jim Cramer Recently Discussed These 17 Stocks And Chinese Hackers. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against the other stocks Jim Cramer recently discussed. Jim Cramer’s appearance on Squawk on the Street aired on January 17th covered a […]

Insider Monkey 3 days ago

NVO
Why Did Novo Nordisk (NVO) Go Down on Friday?

We recently published a list of These 10 Firms Took A Hit on Friday. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against other firms that took a hit on Friday. Wall Street’s main indices all finished in the green territory on Friday, as investors repositioned […]

Insider Monkey 4 days ago

NVO
Ozempic, Xtandi among next 15 drugs selected for U.S. price talks

The Department of Health and Human Services, through the Centers for Medicare & Medicaid Services, announced the selection of 15 additional drugs covered under Medicare Part D for price negotiations. In accordance with the Inflation Reduction Act, the negotiations with participating drug companies for these 15 drugs will occur in 2025 and any negotiated prices will become effective in 2027, the agency said in a statement. The selected drug list for the second cycle of negotiations is: Novo Nordi

TipRanks 4 days ago

NONOF

NVO

BMY
Is Novo Nordisk Stock a Buy?

It hasn't been a great period for investors in Novo Nordisk (NYSE: NVO) despite its ongoing status as one of the pharmaceutical industry's apex competitors in the field of cardiometabolic drugs. Over the last five years, its trailing-12-month revenue grew by 109%, reaching $39.3 billion, thanks to its portfolio of potent drugs for cardiometabolic illnesses like diabetes and obesity. For the company to continue to grow at the same pace it has been recently, its blockbuster drugs, specifically its weight loss drug Wegovy, need to continue to retain a sizable share of the market.

Motley Fool 4 days ago

NVO
Medicare to negotiate prices on 15 drugs, including Ozempic

Medicare seeks to negotiate prices on 15 drugs, including Novo Nordisk's (NVO) GLP-1 weight-loss drugs Ozempic and Wegovy, in new talks. Yahoo Finance senior health reporter Anjalee Khemlani explains the process and the range of other drugs on this new list from pharmaceutical giants Pfizer (PFE), AstraZeneca (AZN), Merck (MRK) To watch more expert insights and analysis on the latest market action, check out more Market Domination here. This post was written by Luke Carberry Mogan.

Yahoo Finance Video 5 days ago

PFE

MRK

AZN

Performance Overview

Return	NOVA.F	OMX Copenhagen 25 Index
YTD	-7.45%	-2.00%
1-Year	-20.32%	-4.16%
3-Year	+91.15%	-2.20%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Novo Nordisk A/S (NOVA.F)

Novo Nordisk (NVO) Stock Dips While Market Gains: Key Facts

GLP-1 Drugs Cut Risk of Alzheimer's, NVO & LLY Shares Rise

This Biotech Stock Soared 116% in 2024, but Is It a Buy in 2025?

Novo Nordisk's GLP-1 Drugs: Health Breakthroughs, Big Buybacks, and Medicare's Price-Cut Threat

Novo, Lilly Weight-Loss Drugs Reduce Risk of Alzheimer’s, Study Shows. What It Means for the Stocks.

Company News for Jan 21, 2025

Will Medicare End Ozempic Maker Novo Nordisk's Obesity Drug Boom?

The race for the next Ozempic is on

LVMH Surges Past Novo Nordisk as Arnault's Wealth Skyrockets--Is Luxury Back on Track?

NVO Stock Down as Medicare Selects Semaglutide Drugs for Price Cuts

Novo Nordisk A/S - share repurchase programme

Company News for Jan 20, 2025

LVMH dethrones Novo Nordisk as Europe’s most valuable company as Bernard Arnault adds $12 billion to net worth in 2025

Trending tickers: Trump Media, Intel, Alibaba, Novo Nordisk and Entain

Novo Nordisk’s high-dose Wegovy increases weight loss and remains safe

Jim Cramer’s Comments on Novo Nordisk A/S (NVO) Surrounded Its Weight Loss Drugs Being Picked For Medicare Price Negotiations

Why Did Novo Nordisk (NVO) Go Down on Friday?

Ozempic, Xtandi among next 15 drugs selected for U.S. price talks

Is Novo Nordisk Stock a Buy?

Medicare to negotiate prices on 15 drugs, including Ozempic

Performance Overview